ADMA Biologics’ (ADMA) shares have lost 8.9% in a month against the industry’s growth of 6.6%.The company has put up a phenomenal performance in 2024 and hit a 52-week high of $23.64 on Nov. 11.Last month, ADMA reported preliminary revenues for 2024 and provided a business update. On a preliminary basis, total revenues in 2024 are estimated to be in the $417-$425 million range (exceeding previous guidance of $415 Million). Total cash holdings at the end of 2024 grew to more than $100 million.ADMA Underperfo ...

Adma Biologics (ADMA) ended the recent trading session at $16.92, demonstrating a +0.3% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 0.36%. Meanwhile, the Dow experienced a drop of 0.28%, and the technology-dominated Nasdaq saw an increase of 0.51%.Coming into today, shares of the infectious disease drug developer had lost 9.11% in the past month. In that same time, the Medical sector gained 5.92%, while the S&P 500 gained 2.11%.Investors will be eagerly watchin ...

This is my first cover of ADMA Biologics (NASDAQ: ADMA ). In the article, I will describe ADMA Biologics' business areas and my opinion on how they will affect the company's future. I will try to compare ADMA's product to the competition andI first entered investing in 2016 as an individual value investor. In 2022, I established the investment firm Libra Capital. I mostly write articles as part of my deep research into a company before I make an investment, whether long or short. For me, a ''hold'' article ...

Core Viewpoint - Adma Biologics is experiencing fluctuations in stock performance, with a recent increase in share price, but a decline over the past month, while upcoming financial results are anticipated to show significant year-over-year growth in earnings and revenue [1][2]. Group 1: Stock Performance - Adma Biologics shares closed at $16.47, reflecting a +1.92% change from the previous day, outperforming the S&P 500's gain of 0.61% [1] - Over the past month, shares have decreased by 7.18%, underperforming both the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08% [1] Group 2: Financial Expectations - Analysts expect Adma Biologics to report earnings of $0.15 per share, indicating a year-over-year growth of 275% [2] - Revenue is forecasted to be $112.2 million, representing a 51.83% increase compared to the same quarter last year [2] Group 3: Analyst Projections - Recent shifts in analyst projections for Adma Biologics are important for investors, as positive changes indicate optimism regarding the company's business and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, suggests a correlation between estimate adjustments and stock price performance [4] Group 4: Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 11.61% in the past 30 days [5] - The company has a Forward P/E ratio of 23.59, which is higher than the industry average of 21.95, indicating it is trading at a premium [6] Group 5: Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]

Core Insights - ADMA Biologics, Inc. reported preliminary unaudited total revenue for FY 2024 between $417 million and $425 million, exceeding previous guidance of $415 million [1] - The company’s total cash holdings at year-end 2024 grew to over $100 million, reflecting a net cash surplus despite discharging $30 million of debt during Q4 2024 [1] - ADMA anticipates generating over $1 billion in total annual revenue prior to 2030, more than doubling the current 2025 revenue forecast [1][7] Financial Performance - FY 2025 and 2026 total revenue guidance is expected to exceed $485 million and $600 million, respectively [3][7] - FY 2025 and 2026 net income is expected to exceed $170 million and $230 million, respectively [3][7] - FY 2025 and 2026 adjusted EBITDA is expected to exceed $220 million and $300 million, respectively [3][7] Business Updates - Newly executed long-term high-titer plasma supply contracts are expected to support ASCENIV revenue growth through the late 2030s [2][7] - A Prior Approval Supplement (PAS) has been submitted to the FDA for an innovative yield enhancement production process, with potential regulatory approval anticipated by mid-2025 [2][7] - The innovative process is expected to increase Immunoglobulin (IG) yields by approximately 20%, driving revenue and earnings increases starting later in 2025 [2][7] Strategic Positioning - ADMA has solidified high-titer plasma supply on a long-term basis, increasing access to raw material plasma from approximately 250 collection centers, a five-fold increase in total collection capacity [7] - The company is focused on optimizing its balance sheet, having generated approximately $45 million in operating cash flow in Q4 2024, leading to a net cash surplus relative to its outstanding debt [7] - ADMA is leveraging its robust intellectual property estate and innovative R&D engine, with potential upside from its lead R&D pipeline program, SG-001, targeting S. pneumonia [7]

Core Viewpoint - ADMA Biologics has experienced a significant stock price increase of 275.7% over the past year, contrasting with a 14.3% decline in the industry, driven by strong quarterly performance and raised guidance [1][3]. Company Performance - ADMA Biologics specializes in plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [4]. - The lead product, Asceniv, is a plasma-derived IVIG that contains polyclonal antibodies, indicated for treating primary immunodeficiency disease (PIDD) in adults and adolescents [5]. Financial Highlights - Total revenues in the third quarter increased by 78%, attributed to higher sales of Asceniv and third-party plasma sales from ADMA's BioCenters [6]. - ADMA has raised its revenue guidance for 2024 to over $415 million and for 2025 to over $465 million, with net income projections exceeding $120 million in 2024 and $165 million in 2025 [9]. Product Development - ADMA is conducting a pediatric study for Asceniv, which may lead to label expansion to include pediatric patients, with a potential application filing expected in the coming quarters [7][8]. Margin and Valuation - The higher-margin product portfolio now constitutes over 50% of total revenues, with plans to increase Asceniv's supply, potentially enhancing margins and earnings growth [10]. - ADMA's shares currently trade at a price/sales ratio of 8.86x forward sales, significantly higher than the industry average of 1.69x [11]. Market Outlook - The market for plasma-derived products has substantial growth potential, particularly in the underserved immune-compromised patient population [14].

Company Overview - ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3] - The company currently manufactures and markets three FDA-approved plasma-derived biologics: BIVIGAM, ASCENIV™, and NABI-HB, targeting immune deficiencies and prevention of certain infectious diseases [3] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and also runs ADMA BioCenters, an FDA-approved source plasma collector [3] Upcoming Events - Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, from January 13-16, 2025, with ADMA's presentation scheduled for January 13, 2025, at 10:30 a.m. PT [1] - A live audio webcast of the presentation will be available on the company's investor website, with an archived version accessible approximately two hours after the event [2]

Industry Overview - Innovation is expected to drive growth in the biotech industry, particularly in obesity and oncology drugs, with strong M&A activity anticipated in 2025 [1] - The overall fundamentals of the biotech sector remain robust, and investor interest is expected to return [1][16] ADMA Biologics - ADMA Biologics markets plasma-derived biologics for immune deficiencies and infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [2] - The company has shown exceptional performance in 2024, with shares increasing by 292% year to date [3] - Earnings per share estimates for 2025 have risen from 64 cents to 78 cents in the last 60 days [4] - ADMA is working to increase Asceniv's supply, which is expected to significantly contribute to total revenues and margin expansion [20] Tarsus Pharmaceuticals - Tarsus Pharmaceuticals markets Xdemvy, an eye drop for Demodex blepharitis, which generated $113.7 million in sales in the first nine months of 2024 [5][22] - The company has experienced a share price increase of 168.7% in 2024, supported by positive regulatory updates and pipeline progress [7][23] - Loss per share estimates for 2025 have narrowed from $2.10 to $1.43 in the past 60 days [7] Stoke Therapeutics - Stoke Therapeutics is developing zorevunersen for Dravet syndrome, currently in phase I/IIa studies, with Breakthrough Therapy designation granted by the FDA [8][9] - The company has seen a share price increase of 120.7% year to date, with expectations for further gains in 2025 [11][26] - Loss per share estimates for 2025 have narrowed from $2.59 to $2.49 in the past 60 days [11] ChromaDex - ChromaDex markets Niagen as a leading NAD+ booster and is developing nicotinamide riboside chloride (NRC) for ataxia telangiectasia, with FDA designations granted [12][14] - The company has experienced a share price increase of 270.6% in 2024, driven by strong sales and e-commerce growth [15][28] - Earnings per share estimates for 2025 have increased from 9 cents to 12 cents in the past 60 days [15]

Core Insights - ADMA Biologics has repaid $30 million of its senior secured term loan facility, reducing total gross debt to $75 million, which represents a 29% reduction from previous levels [1][5] - The repayment was funded using cash on hand, indicating strong cash flow generation capabilities [2] - The company anticipates that the reduction in debt will lower interest expenses and enhance earnings growth potential in the near future [2] Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2] - The company currently markets three FDA-approved plasma-derived biologics: BIVIGAM®, ASCENIV™, and NABI-HB® [2] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, that collects source plasma [2]

Industry Overview - The biotech sector experienced volatility in 2024, starting positively but declining by 10.5% due to a slowdown in collaboration deals despite new drug approvals and increased M&A activity [1] - The continuous demand for innovative medical treatments is expected to keep investor interest in the biotech industry, despite macroeconomic uncertainties [2] M&A Activity - M&A activity is anticipated to accelerate in 2025 due to a change in administration and expected deregulation, with major pharma and biotech companies looking to enhance their product portfolios [3] - Companies focusing on oncology, immunooncology, obesity drugs, and gene-editing are likely to attract attention, benefiting smaller biotech firms with promising candidates [3] Company Highlights Sarepta Therapeutics (SRPT) - Sarepta's portfolio was significantly enhanced by the FDA approval of Elevidys, the first gene therapy for Duchenne muscular dystrophy (DMD), which has shown blockbuster potential [5] - The company is developing additional gene therapy programs and plans to submit a regulatory filing for its LGMD candidate in mid-2025 [6] - Sarepta's shares surged 24.7% in 2024, with a current average target price of $184.15, indicating a potential upside of 46.43% [7] ADMA Biologics (ADMA) - ADMA markets plasma-derived biologics for immune deficiencies, with Asceniv showing strong sales growth and potential label expansion for pediatric patients [9][10] - The higher-margin product portfolio now constitutes over 50% of total revenues, with shares increasing by 291.6% in 2024 [11] - The current average target price for ADMA is $25, representing an upside of 34.19% [12] Exelixis (EXEL) - Exelixis has performed well due to its lead drug, Cabometyx, which is a leading treatment for renal cell carcinoma [13] - The FDA accepted a supplemental new drug application for Cabometyx, with a target action date of April 3, 2025, which could enhance growth prospects [14] - Shares have increased by 40.3% in 2024, with EPS estimates rising for 2024 and 2025 [16] Alnylam Pharmaceuticals (ALNY) - Alnylam's marketed drugs, including Amvuttra, are performing well, with efforts to expand Amvuttra's label to boost sales [17] - The company has collaborations with major firms to advance its pipeline, which includes promising candidates like cemdisiran and mivelsiran [18] - Alnylam's shares have surged 24.3% year to date, with a current average target price of $296.32, indicating a potential upside of 24.55% [19]